<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04135989</url>
  </required_header>
  <id_info>
    <org_study_id>197/19</org_study_id>
    <nct_id>NCT04135989</nct_id>
  </id_info>
  <brief_title>Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES</brief_title>
  <acronym>PARTHENOPE</acronym>
  <official_title>Randomized 2x2 Factorial Trial Comparing the Cre8 Amphilimus-sirolimus Eluting Stent vs. the Synergy Everolimus-eluting Stent and a Personalized vs. Standard Duration of Dual Antiplatelet Therapy in All-comers Patients Undergoing Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AdvicePharma Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      New-generation metallic drug-eluting stents represent the standard of care among patients
      undergoing percutaneous coronary intervention (PCI). Currently, few data are available as
      regards to the safety and efficacy of the Cre8 amphilimus-eluting stent (Cre8 AES,
      Alvimedica, Instanbul, Turkey) in comparison with the biodegradable polymer
      everolimus-eluting stent (Synergy EES, Boston Scientific, Marlborough, MA, USA). Results from
      randomized trials and meta-analyses consistently indicate that prolonged dual antiplatelet
      therapy (DAPT) after PCI reduces ischemic events, but invariably conveys an excess of
      clinically relevant bleeding, which is proportional to the duration of treatment. It has been
      estimated, indeed, that for every non-fatal ischemic event avoided with prolonged DAPT, two
      or more clinically relevant bleeding events have to be expected. Given the trade-off between
      benefits and risks and the lack of mortality benefit in favor of prolonged DAPT, expert
      consensus suggests that DAPT duration should be individualized based on ischemic versus
      bleeding risks. At this regard, the DAPT score has been recently proposed as standardized
      tool to identify patients who derive benefit or lack from a prolonged course of DAPT.
      However, a prospective assessment of the DAPT score is lacking and whether a personalized
      duration of DAPT based on the DAPT score improves the net clinical benefit remains unknown.

      The objective of the study is to compared the safety and the efficacy of the Cre8 AES with
      the Synergy EES and a personalized DAPT duration based on the DAPT score with a standard DAPT
      duration among patients undergoing PCI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the trial is:

      i) to evaluate the efficacy and safety of the Cre8 AES vs. the Synergy EES in a broadly
      unselected patient population with coronary artery disease undergoing PCI; ii) to compare the
      safety and efficacy of a personalized DAPT duration (3-, 6-, or 24-month) guided by the
      application of the DAPT score with a standard DAPT duration (12-month) after PCI.

      In particular, the objectives of the trial are to test the following hypothesis:

        -  The Cre8 AES is non-inferior to the Synergy EES with regards to a device-oriented
           composite endpoint (DOCE) at 1-year follow-up.

        -  A personalized DAPT duration based on the DAPT score is superior to a standard DAPT
           duration with regards to a net adverse clinical endpoint (NACE) at 2-year follow-up.

      This is a prospective, randomized, multicenter, investigator-initiated, assessor-blind trial
      to be conducted at interventional cardiology centers in Italy. Patients undergoing PCI will
      be randomized in a 2-by-2 randomization fashion to undergo PCI with the Cre8 AES or Synergy
      EES and to receive a personalized or standard DAPT duration. All patients will be followed at
      3-, 6-, 12- and 24-month after PCI for clinical endpoints.

      Use of experimental and control DES:

      Both the study stent (Cre8 AES) and the control stent (Synergy EES) will be used according to
      their indications for use. The randomly assigned stent is not expected to have an influence
      on the conduct of the procedure that will take place according to the routine practice.
      Eligible patients will undergo PCI as per local protocol, according to current guidelines of
      the European Society of Cardiology on myocardial revascularization. The technique of PCI
      (vascular access route, choice of the vascular sheath diameter, choice of the diagnostic and
      guiding catheters sizes and shapes, choice of the coronary guidewire) will be left to the
      discretion of the operator as per standard individual and local practice. The operator will
      choose the appropriate length and diameter of the stents to be implanted by visual estimate
      or quantitative coronary angiography as per local practice. The Cre8 AES and the Synergy EES
      systems are commercially available and all sizes may be used for the study.

      DAPT duration according to randomization:

      DAPT duration in patients randomized to personalized DAPT regimen: In patients that are
      randomized to a personalized DAPT and have a low DAPT score (&lt;2), DAPT duration is
      recommended for 3 months in case of stable coronary artery disease at the time of the index
      procedure or for 6 months in case of acute coronary syndrome at the time of the index
      procedure. A low dose of aspirin (75 to 162 mg daily) will be administered throughout the
      course of the study. In patients that are randomized to a personalized DAPT and have a high
      DAPT score (â‰¥2), DAPT duration is recommended for 24 months. Changes in the dose or in the
      type of P2Y12 receptor inhibitor (clopidogrel, prasugrel, or ticagrelor) are allowed during
      the course of the study. A low dose of aspirin (75 to 162 mg daily) will be administered
      throughout the course of the study. At 12-month, patients on treatment with prasugrel or
      ticagrelor should continue the same P2Y12 receptor inhibitor. In this specific scenario, it
      is preferable to continue with the same P2Y12 receptor inhibitor (prasugrel 10 mg daily or
      ticagrelor 90 mg daily) or to switch to a low-dose regimen of ticagrelor (60 mg twice daily)
      if clinically indicated or to switch to clopidogrel (75 mg daily).

      DAPT regimen in patients in patients randomized to a standard DAPT duration: In patients that
      are randomized to a standard DAPT duration, oral P2Y12 inhibitors (clopidogrel, prasugrel, or
      ticagrelor) should be administered for 12-month. A low dose of aspirin (75 to 162 mg daily)
      will be administered throughout the course of the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2019</start_date>
  <completion_date type="Anticipated">October 24, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 24, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>2-by-2 randomization</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Device-oriented composite endpoint (DOCE) for the comparison between the Cre8 AES and the Synergy EES.</measure>
    <time_frame>12 months</time_frame>
    <description>The composite of cardiovascular death, myocardial infarction not clearly attributable to a non-target vessel, or clinically-driven target-lesion revascularization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Net adverse clinical endpoint (NACE) for the comparison between a personalized and standard DAPT duration.</measure>
    <time_frame>24 months</time_frame>
    <description>The composite of all-cause death, any myocardial infarction, stroke, urgent target-vessel revascularization, or BARC type 2 to 5 bleeding at 24-month follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with All-cause death</measure>
    <time_frame>12- and 24-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Death from cardiovascular causes</measure>
    <time_frame>12- and 24-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Myocardial infarction</measure>
    <time_frame>12- and 24-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Stroke</measure>
    <time_frame>12- and 24-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically-driven target-lesion revascularization</measure>
    <time_frame>12- and 24-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Definite or probable stent thrombosis</measure>
    <time_frame>12- and 24-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Definite stent thrombosis</measure>
    <time_frame>12- and 24-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Any revascularization</measure>
    <time_frame>12- and 24-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically-driven target-vessel revascularization</measure>
    <time_frame>12- and 24-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Urgent target-vessel revascularization</measure>
    <time_frame>12- and 24-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Urgent non-target-vessel revascularization</measure>
    <time_frame>12- and 24-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Any target-lesion revascularization</measure>
    <time_frame>12- and 24-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Any target-vessel revascularization</measure>
    <time_frame>12- and 24-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Bleeding events</measure>
    <time_frame>12- and 24-month</time_frame>
    <description>Bleeding events according to the BARC, TIMI and GUSTO classification</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">2106</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Chronic Coronary Syndrome</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Cre8 AES and personalized DAPT duration</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Percutaneous coronary intervention with implantation of a Cre8 amphilimus- eluting stent for coronary artery disease.
Personalized duration of dual antiplatelet therapy for 3-, 6-, or 24-month after percutaneous coronary intervention based on the DAPT score.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cre8 AES and standard DAPT duration</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Percutaneous coronary intervention with implantation of a Cre8 amphilimus- eluting stent for coronary artery disease.
Standard duration of dual antiplatelet therapy for 12-month after percutaneous coronary intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Synergy EES and personalized DAPT duration</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Percutaneous coronary intervention with implantation of a Synergy everolimus-eluting stent for coronary artery disease.
Personalized duration of dual antiplatelet therapy for 3-, 6-, or 24-month after percutaneous coronary intervention based on the DAPT score.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Synergy EES and standard DAPT duration</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Percutaneous coronary intervention with implantation of a Synergy everolimus-eluting stent for coronary artery disease.
Standard duration of dual antiplatelet therapy for 12-month after percutaneous coronary intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous coronary intervention with implantation of amphilimus-eluting stents for coronary artery disease.</intervention_name>
    <description>Implantation of polymer-free, amphilimus-eluting, drug-eluting stents</description>
    <arm_group_label>Cre8 AES and personalized DAPT duration</arm_group_label>
    <arm_group_label>Cre8 AES and standard DAPT duration</arm_group_label>
    <other_name>Cre8 AES</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous coronary intervention with implantation of everolimus-eluting stents for coronary artery disease.</intervention_name>
    <description>Implantation of biodegradable-polymer, everolimus-eluting, drug-eluting stents</description>
    <arm_group_label>Synergy EES and personalized DAPT duration</arm_group_label>
    <arm_group_label>Synergy EES and standard DAPT duration</arm_group_label>
    <other_name>Synergy EES</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Personalized DAPT duration</intervention_name>
    <description>Duration of dual antiplatelet therapy according to DAPT score for 3- or 6- months in patients with low DAPT score (stable CAD or ACS, respectively) or for 24-months in patients with high DAPT score</description>
    <arm_group_label>Cre8 AES and personalized DAPT duration</arm_group_label>
    <arm_group_label>Synergy EES and personalized DAPT duration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard DAPT duration</intervention_name>
    <description>Duration of dual antiplatelet therapy for 12 months.</description>
    <arm_group_label>Cre8 AES and standard DAPT duration</arm_group_label>
    <arm_group_label>Synergy EES and standard DAPT duration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age â‰¥18 years;

          2. Clinical evidence of coronary artery disease requiring PCI with DES implantation;

          3. Any coronary lesion sized 2.25-4.5 mm by visual estimation.

        Exclusion Criteria:

          1. Inability to provide informed consent;

          2. Active bleeding requiring medical attention (BARC â‰¥2);

          3. Need for chronic oral anticoagulant therapy;

          4. Planned surgery within 3 months;

          5. Known hypersensitivity or allergy to aspirin or any P2Y12 receptor inhibitor
             (clopidogrel, prasugrel, ticagrelor), heparin, contrast agent, or any DES-components;

          6. Previous treatment with bioresorbable vascular scaffolds;

          7. Participation in another study that has not reached the primary endpoint;

          8. A life expectancy of less than 24 months;

          9. Female of childbearing potential;

         10. Under judicial protection, tutorship or curatorship.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Giovanni Esposito, MD, PhD</last_name>
    <phone>+390817463075</phone>
    <email>espogiov@unina.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raffaele Piccolo, MD, PhD</last_name>
    <phone>+390817464325</phone>
    <email>raffaele.piccolo@unina.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Casa di Cura Villa Dei Fiori</name>
      <address>
        <city>Acerra</city>
        <state>Naples</state>
        <zip>80011</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciro De Simone, MD</last_name>
      <phone>+390813190483</phone>
      <email>ciro.desimone@hotmail.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale S.Maria delle Grazie</name>
      <address>
        <city>Pozzuoli</city>
        <state>Naples</state>
        <zip>80078</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Boccalatte</last_name>
      <phone>+390818552110</phone>
      <email>marco.boccalatte@aslnapoli2nord.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Maria SS. Addolorata&quot;</name>
      <address>
        <city>Eboli</city>
        <state>SA</state>
        <zip>84025</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Bottiglieri, MD</last_name>
      <email>giuseppebottiglieri3@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.R.N. S.Giuseppe Moscati-CittÃ  Ospedaliera</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emilio Di Lorenzo, MD</last_name>
      <phone>+390825203100</phone>
      <email>emiliodilorenzo4327@aosgmoscati.av.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giuseppe Moscati</name>
      <address>
        <city>Aversa</city>
        <zip>81031</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianluca Caiazzo, MD</last_name>
      <phone>+390815001743</phone>
      <email>gianluca.caiazzo@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.R.N. Sant'Anna e San Sebastiano</name>
      <address>
        <city>Caserta</city>
        <zip>81100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo CalabrÃ², MD, PhD</last_name>
      <phone>+390823232395</phone>
      <email>paolo.calabro@unicampania.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giuliano</name>
      <address>
        <city>Giugliano In Campania</city>
        <zip>80014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Napolitano, MD</last_name>
      <phone>+3908189553</phone>
      <email>giovanni.napolitano@aslnapoli2nord.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Federico II University of Naples</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Esposito, MD PhD</last_name>
      <phone>0817463075</phone>
      <phone_ext>0039</phone_ext>
      <email>espogiov@unina.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Esposito, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.R.N. A. Cardarelli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciro Mauro, MD</last_name>
      <phone>+390817472808</phone>
      <email>ciro.mauro3@tin.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni Bosco - ASL Napoli 1</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrico Russolillo, MD</last_name>
      <phone>+39 3476878434</phone>
      <email>erlillo@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale del Mare</name>
      <address>
        <city>Napoli</city>
        <zip>80147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernardino Tuccillo, MD</last_name>
      <phone>+3908118775265</phone>
      <email>bernardino.tuccillo@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria della PietÃ </name>
      <address>
        <city>Nola</city>
        <zip>80035</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Attilio Varricchio, MD</last_name>
      <phone>+390818223218</phone>
      <email>attiliovarricchio13@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU San Giovanni di Dio e Ruggi d'Aragona</name>
      <address>
        <city>Salerno</city>
        <zip>84131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cesare Baldi, MD</last_name>
      <phone>+39089673186</phone>
      <email>cesare.baldi@tiscali.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Piccolo R, Windecker S. Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: A Tale of 2 Decades With New Perspectives in the Era of New-Generation Drug-Eluting Stents. Circ Cardiovasc Interv. 2016 Feb;9(2):e003587. doi: 10.1161/CIRCINTERVENTIONS.116.003587.</citation>
    <PMID>26858081</PMID>
  </reference>
  <reference>
    <citation>Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, JÃ¼ni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018 Jan 14;39(3):213-260. doi: 10.1093/eurheartj/ehx419.</citation>
    <PMID>28886622</PMID>
  </reference>
  <reference>
    <citation>Spencer FA, Prasad M, Vandvik PO, Chetan D, Zhou Q, Guyatt G. Longer- Versus Shorter-Duration Dual-Antiplatelet Therapy After Drug-Eluting Stent Placement: A Systematic Review and Meta-analysis. Ann Intern Med. 2015 Jul 21;163(2):118-26. doi: 10.7326/M15-0083. Review.</citation>
    <PMID>26005909</PMID>
  </reference>
  <reference>
    <citation>Bittl JA, Baber U, Bradley SM, Wijeysundera DN. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016 Sep 6;68(10):1116-39. doi: 10.1016/j.jacc.2016.03.512. Epub 2016 Mar 29. Review.</citation>
    <PMID>27036919</PMID>
  </reference>
  <reference>
    <citation>Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O'Gara PT, Sabatine MS, Smith PK, Smith SC Jr. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016 Sep 6;68(10):1082-115. doi: 10.1016/j.jacc.2016.03.513. Epub 2016 Mar 29.</citation>
    <PMID>27036918</PMID>
  </reference>
  <reference>
    <citation>RÃ¤ber L, Piccolo R. CardioPulse: Different bleeding scores and which one should we use? Eur Heart J. 2016 Jan 21;37(4):327-31.</citation>
    <PMID>27462674</PMID>
  </reference>
  <reference>
    <citation>Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L; DAPT Study Investigators. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016 Apr 26;315(16):1735-49. doi: 10.1001/jama.2016.3775. Erratum in: JAMA. 2016 Jul 19;316(3):350. JAMA. 2016 Jul 19;316(3):350.</citation>
    <PMID>27022822</PMID>
  </reference>
  <reference>
    <citation>Piccolo R, Gargiulo G, Franzone A, Santucci A, Ariotti S, Baldo A, Tumscitz C, Moschovitis A, Windecker S, Valgimigli M. Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention. Ann Intern Med. 2017 Jul 4;167(1):17-25. doi: 10.7326/M16-2389. Epub 2017 Jun 13.</citation>
    <PMID>28605779</PMID>
  </reference>
  <reference>
    <citation>Rozemeijer R, Stein M, Voskuil M, van den Bor R, Frambach P, Pereira B, Koudstaal S, Leenders GE, Timmers L, Rittersma SZ, Kraaijeveld AO, Agostoni P, Roes KC, Doevendans PA, Stella PR; ReCre8 Study Investigators. Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent. Circulation. 2019 Jan 2;139(1):67-77. doi: 10.1161/CIRCULATIONAHA.118.037707.</citation>
    <PMID>30586704</PMID>
  </reference>
  <reference>
    <citation>Navarese EP, Andreotti F, Schulze V, KoÅ‚odziejczak M, Buffon A, Brouwer M, Costa F, Kowalewski M, Parati G, Lip GY, Kelm M, Valgimigli M. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ. 2015 Apr 16;350:h1618. doi: 10.1136/bmj.h1618. Erratum in: BMJ. 2016 Oct 17;355:i5600.</citation>
    <PMID>25883067</PMID>
  </reference>
  <reference>
    <citation>Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, Onuma Y, Morel MA, van Es GA, Zuckerman B, Fearon WF, Taggart D, Kappetein AP, Krucoff MW, Vranckx P, Windecker S, Cutlip D, Serruys PW; Academic Research Consortium. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Circulation. 2018 Jun 12;137(24):2635-2650. doi: 10.1161/CIRCULATIONAHA.117.029289. Review.</citation>
    <PMID>29891620</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 21, 2019</study_first_submitted>
  <study_first_submitted_qc>October 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Giovanni Esposito</investigator_full_name>
    <investigator_title>Professor of Cardiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

